Publications

2024

Rahman MM, Wells G, Rantala JK, Helleday T, Muthana M, Danson SJ (2024) In-vitro assays for immuno-oncology drug efficacy assessment and screening for personalized cancer therapy: scopes and challenges. Expert Rev Clin Immunol Apr 3:1-18. PMID: 38546609

–

Marttila P, Bonagas N, Chalkiadaki C, Stigsdotter H, Schelzig K, Shen J, Farhat CM, Hondema A, Albers J, Wiita E, Rasti A, Warpman Berglund U, Slipicevic A, Mortusewicz O, Helleday T (2024) The one-carbon metabolic enzyme MTHFD2 promotes resection and homologous recombination after ionizing radiation. Mol Oncol. PMID: 38533616

–

Fabbrizi MR, Nickson CM, Hughes JR, Robinson EA, Vaidya K, Rubbi CP, Kacperek A, Bryant HE, Helleday T, Parsons JL (2024) Targeting OGG1 and PARG radiosensitises head and neck cancer cells to high-LET protons through complex DNA damage persistence. Cell Death Dis 15, 150. PMID: 38368415

–

Zhang SM, Paulin CBJ, Shu H, Yagüe-Capilla M, Michel M, Marttila P, Ortis F, Bwanika HC, Dirks C, Venkatram RP, Wiita E, Jemth AS, Almlöf I, Loseva O, Hormann FM, Koolmeister T, Linde E, Lee S, Llona-Minguez S, Haraldsson M, Axelsson H, Strömberg K, Homan EJ, Scobie M, Lundbäck T, Helleday T, Rudd SG (2024) Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnel. iScience 27, 108907. PMID: 38318365

–

Ramos L, Henriksson M, Helleday T, Green AC (2024) Targeting MTHFD2 to Exploit Cancer-Specific Metabolism and the DNA Damage Response. Cancer Res 84, 9-16. PMID: 37922465

2023

Helleday T (2023) Mitotic inhibitors in treatment of cancer. Cancer Treat Res 186, 223-237. PMID: 37978139

–

Gagg H, Williams ST, Conroy S, Myers KN, McGarrity-Cottrell C, Jones C, Helleday T, Rantala J, Rominiyi O#, Danson SJ#, Collis SJ, Wells G# (2023) Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients. F1000Res 12, 954. PMID: 37799492

–

Odell LR#, Skillinghaug B, Matt C, Wu P, Koolmeister T, Desroses M, Llona-Minguez S, Wallner O, Helleday T, Scobie M# (2023) Synthesis of Substituted Indazole Acetic Acids by N-N Bond Forming Reactions. Eur J Org Chem 26, e2023002. doi.org/10.1002/ejoc.202300291

–

Largeot A, Klapp V, Viry E, Gonder S, Fernandez Botana I, Blomme A, Benzarti M, Pierson S, Duculty C, Marttila P, Wierz M, Gargiulo E, Pagano G, An N, El Hachem N, Perez Hermandez D, Chakraborty S, Ysebaert L, François JH, Cortez Clemente SD, Berchem G, Efremov DG, Dittmar G, Szpakowska M, Chevigne A, Nazarov PV, Helleday T, Close P, Meiser J, Stamatopoulos B, Désaubry L, Paggetti J#, Moussay E# (2023) Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as therapeutic strategy in CLL. Blood 141, 3166-3183. PMID: 37084385

–

Green AC, Marttila P, Kiweler N, Chalkiadaki C, Wiita E, Cookson V, Lesur A, Eiden K, Bernardin F, Vallin KSA, Borhade S, Long M, Ghahe EK, Jiménez-Alonso JJ, Jemth AS, Loseva O, Mortusewicz O, Meyers M , Viry E, Johansson AI, Hodek O, Homan E, Bonagas N, Ramos L, Sandberg L, Frödin M, Moussay E, Slipicevic A, Letellier E, Paggetti J, Storgaard Sørensen C, Helleday T#, Henriksson M#, Meiser J# (2023) Formate overflow drives toxic folate trapping in MTHFD1-inhibited cancer cells. Nat Metab 5, 642-659. PMID: 37012496

–

Erlandsson A# , Lundholm M, Watz J, Bergh A, Petrova E , Alamdari F , Helleday T, Davidsson S, Andren O, Tarish F (2023) Infiltrating immune cells in prostate cancer tissue after androgen deprivation and radiotherapy. Int J Immunopathol Pharmacol 37, 3946320231158025. PMID: 36880147

–

Pateras I#, Williams C, Gianniou DD, Margetis A, Avgeris M, Rousakis P, Legaki AI, Mirtschink P, Zhang W, Panoutsopoulou K, Delis AD, Pagakis SN, Tang W, Ambs S, Warpman Berglund U, Helleday T, Varvarigou A, Chatzigeorgiou 8, Nordström A, Tsitsilonis OE, Trougakos IP, Gilthorpe JG , Frisan T# (2023) Short term starvation potentiates the efficacy of chemotherapy in triple negative breast cancer via metabolic reprogramming. J Transl Med 21, 169. PMID: 36869333

–

Walter M, Mayr F, Hanna BMF, Cookson V, Mortusewicz O, Helleday T, Herr P#. (2023). NUDT22 promotes cancer growth through pyrimidine salvage. Oncogene 42, 1282-1293. PMID: 36871087

–

Tanner L#, Single AB , Bonghir RKV , Oomen R , Wallner O , Helleday T, Kalderen C , Egesten A (2023) Small-molecule-mediated OGG1 inhibition attenuates pulmonary inflammation and lung fibrosis. Nat Commun 14, 643. PMID: 36746968

–

Wallner O, Cázares-Körner A, Scaletti ER, Masuyer G, Bekkhus T, Visnes T, Mamonov K, Ortis F, Lundbäck T, Volkova M, Koolmeister T, Wiita E, Loseva O, Pandey M, Homan E, Benítez-Buelga C, Davies J, Scobie M, Warpman Berglund U, Kalderén C, Stenmark P, Helleday T, Michel M# (2023) Optimization of N-Piperidinyl-Benzimidazolone Derivatives as Potent and Selective Inhibitors of 8-Oxo Guanine DNA Glycosylase 1. ChemMedChem 18, e202200310. PMID: 36128847

2022

Mobashir M#, Turunen SP, Asrar Izhari M, Ashankyty IM, Helleday T, Lehti K. (2022). An Approach for Systems-Level Understanding of Prostate Cancer from High-Throughput Data Integration to Pathway Modeling and Simulation. Cells. 11(24):4121

–

Henriksson S, Calderón-Montaño JM, Solvie D, Warpman Berglund U, Helleday T#. (2022). Overexpressed c-Myc Sensitizes Cells to TH1579, a Mitotic Arrest and Oxidative DNA Damage Inducer. Biomolecules. 12(12):1777

–

Tanner L#, Bergwik J, Bhongir R, Pan L, Dong C, Wallner O, Kalderén C, Helleday T, Boldogh I Adner, M Egesten A. (2022). Pharmacological OGG1 inhibition decreases murine allergic airway inflammation. Pharmacol. 13:999180.

–

Williams ST, Wells G, Conroy S, Gagg H, Allen R, Rominiyi O, Helleday T, Hullock K, Pennington CEW, Rantala J, Collis SJ#, Danson SJ#. (2022). Precision oncology using ex vivo technology: a step towards individualised cancer care? Expert Rev Mol Med. 24: e39

–

Marklund M, Schultz N, Friedrich S, Berglund E, Tarish F, Tanoglidi A, Liu Y, Bergenstråhle L, Erickson A, Helleday T, Lamb AD, Sonnhammer E#, Lundeberg J#. (2022). Spatio-temporal analysis of prostate tumors in situ suggests pre-existence of treatment-resistant clones. Nat Commun. 13(1):5475

–

Wallner O, Cázares-Körner A, Scaletti ER, Masuyer G, Bekkhus T, Visnes T, Mamonov K, Ortis F, Lundbäck T, Volkova M, Koolmeister T, Wiita E, Loseva O, Pandey M, Homan E, Benítez-Buelga C, Davies J, Scobie M, Warpman Berglund U, Kalderén C, Stenmark P, Helleday T, Michel M#. (2022). Optimization of N-Piperidinyl-Benzimidazolone Derivatives as Potent and Selective Inhibitors of 8-Oxo Guanine DNA Glycosylase 1. ChemMedChem. e202200310

–

Karsten S, Fiskesund R, Zhang XM, Marttila P, Sanjiv K, Pham T, Rasti A, Bräutigam L, Almlöf I, Marcusson-Ståhl M, Sandman C, Platzack B, Harris RA, Kalderén C, Cederbrant K, Helleday T, Warpman Berglund U#. (2022). MTH1 as a target to alleviate T cell driven diseases by selective suppression of activated T cells. Cell Death Differ. 29(1):246-261

–

Benitéz-Buelga C#, Helleday T, Michel M#. (2022). Synthetic switches of OGG1 control initiation of base excision repair and offer new treatment strategies. Clin Transl Med. 12(8):e1035

–

Erickson A , He M, Berglund E, Marklund M, Mirzazadeh R, Schultz N, Kvastad L, Andersson A, Bergenstråhle L, Bergenstråhle J, Larsson L, Galicia LA, Shamikh A, Basmaci E, Díaz De Ståhl T, Rajakumar T, Doultsinos D, Thrane K, Ji A, Khavari PA, Tarish F, Tanoglidi A, Maaskola J , Colling R, Mirtti T, Hamdy FC, Woodcock DJ, Helleday T, Mills IG, Lamb AD#, Lundeberg J#. (2022). Spatially resolved clonal copy number alterations in benign and malignant tissue. Nature. 608(7922):360–367

–

Huang B, Lyu Z, Qian Q, Chen Y, Zhang J, Li B, Li Y, Liang J, Liu Q, Li Y, Chen R , Lian M, Xiao X , Miao Q, Wang Q, Fang J, Lian Z, Li Y, Tang R, Helleday T, Gershwin ME#, You Z#, Ma X#. (2022). NUDT1 promotes the accumulation and longevity of CD103 + TRM cells in primary biliary cholangitis. Journal of Hepatology. S0168-8278(22)00408-1

–

Michel M#, Benitez-Buelga C, Calvo PA, Hanna BMF, Mortusewicz O, Masuyer G, Davies J, Wallner O, Sanjiv K, Castañeda-Zegarra S, Jemth AS, Visnes T, Sastre-Perona A, Albers JJ, Danda AN, Homan EJ, Marimuthu K, Zhenjun Z, Chi CN, Sarno A, Wiita E, von Nicolai C, Komor A, Rajagopal V, Müller S, Hank EC, Varga M, Scaletti ER, Pandey M, Karsten S, Haslene-Hox H, Loevenich S, Marttila P, Rasti A, Mamonov K, Ortis F, Schömberg F, Loseva O, Stewart J, D’Arcy-Evans N, Koolmeister T, Henriksson M, Michel D, de Ory A, Acero L, Calvete O, Scobie M, Hertweck C, Vilotijevic I, Kalderén C, Osorio A, Perona R, Stolz A, Stenmark P, Warpman Berglund U, de Vega M, Helleday T#. (2022). Small molecule activation of OGG1 increases base excision repair by gaining a new enzymatic function. Science. 376(6600):1471-1476

–

Jemth AS#, Scaletti ER, Homan E, Stenmark P, Helleday T, Michel M#. (2022) Nudix hydrolase 18 catalyzes the hydrolysis of active triphosphate metabolites of the antivirals remdesivir, ribavirin, and molnupiravir. J Biol Chem. 298(8):102169

–

Scaletti ER, Gustafsson Westergren R , Andersson Y, Wiita E, Henriksson M, Homan E, Jemth AS, Helleday T# , Stenmark P#. (2022). The First Structure of Human MTHFD2L and Its Implications for the Development of Isoform-Selective Inhibitorsk. ChemMedChem. e202200274

–

Baquero JM, Marchena-Perea E, Mirabet R, Torres-Ruiz R, Blanco-Aparicio C, Rodriguez-Perales S, Helleday T, Benitez-Buelga C, Benitez J, Osorio A#. (2022). OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells. Frontiers in Oncology. 12:888810

–

Centio A, Estruch M, Reckzeh K, Sanjiv K, Vittori C, Engelhard S, Warpman Berglund U, Helleday T, Theilgaard-Mönch K#. (2022). Inhibition of oxidized nucleotide sanitation by TH1579 and conventional chemotherapy cooperatively enhance oxidative DNA-damage and survival in AML. Molecular cancer therapeutics. 21(5):703-714

–

Bonagas N, Gustafsson NMS, Henriksson M, Marttila P, Gustafsson R, Wiita E, Borhade S, Green AC, Vallin K, Sarno A, Svensson R, Göktürk C, Pham T, Jemth A-S, Loseva O, Cookson V, Kiweler N, Sandberg L, Rasti A, Unterlass JE, Haraldsson M, Andersson Y, Scaletti ER, Bengtsson C, Paulin CBJ, Sanjiv K, Abdurakhmanov E, Pudelko L, Kunz B, Desroses M, Iliev P, Färnegårdh K, Krämer A, Garg N, Michel M, Sahlberg SH, Jarvius M, Kalderén C, Bögedahl Jensen A, Almlöf I, Karsten S, Zhang SM, Häggblad M, Eriksson A, Liu J, Glinghammar B, Nekhotiaeva N, Klingegård F, Koolmeister T, Martens U, Llona-Minguez S, Moulson R, Nordström H, Parrow V, Dahllund L, Sjöberg B, Vargas IL, Vo DD, Wannberg J, Knapp S, Krokan HE, Arvidsson PI, Scobie M, Meiser J, Stenmark P, Warpman Berglund U, Homan EJ, Helleday T#. (2022). Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress. Nature Cancer. 3(2):156-17

2021

Zhang SM, Rehling D, Jemth AS, Throup A, Landázuri N, Almlöf I, Göttmann M, Valerie NCK, Borhade SR, Wakchaure P, Page BDG, Desroses M, Homan EJ, Scobie M, Rudd SG, Berglund UW, Söderberg-Nauclér C, Stenmark P, Helleday T#. (2021). NUDT15-mediated hydrolysis limits the efficacy of anti-HCMV drug ganciclovir. Cell Chem Biol. 28(12):1693-1702.e6

–

Chen Y, Hua X, Huang B, Karsten S, You Z, Li B, Li Y, Li Y, Liang J, Zhang J, Wei Y, Chen R, Lyu Z, Xiao X, Lian M, Wei J, Fang J, Miao Q, Wang Q, Berglung UW, Tang R, Helleday T, Ma X#. (2021). MutT Homolog 1 Inhibitor Karonudib Attenuates Autoimmune Hepatitis by Inhibiting DNA Repair in Activated T Cells. Hepatol Commun. hep4.1862

–

Hansel C, Hlouschek J, Xiang K, Melnikova M, Thomale J, Helleday T, Jendrossek V, Matschke J#. (2021). Adaptation to Chronic-Cycling Hypoxia Renders Cancer Cells Resistant to MTH1-Inhibitor Treatment Which Can Be Counteracted by Glutathione Depletion. Cells. 10(11):3040

–

Das I, Tuominen R, Helleday T, Hansson J, Warpman Berglund U, Egyházi Brage S#. (2022). Coexpression of MTH1 and PMS2 Is Associated with Advanced Disease and Disease Progression after Therapy in Melanoma. J Invest Dermatol. 142(3 Pt A):736-740.e6

–

Sanjiv K, Calderón-Montaño JM, Pham TM, Erkers T, Tsuber V, Almlöf I, Höglund A, Heshmati Y, Seashore-Ludlow B, Nagesh Danda A, Gad H, Wiita E, Göktürk C, Rasti A, Friedrich S, Centio A, Estruch M, Våtsveen TK, Struyf N, Visnes T, Scobie M, Koolmeister T, Henriksson M, Wallner O, Sandvall T, Lehmann S, Theilgaard-Mönch K, Garnett MJ, Östling P, Walfridsson J, Helleday T, Warpman Berglund U#. (2021). MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia. Cancer Res. 81(22):5733-5744

–

van den Boogaard ML, Oka R, Hakkert A, Schild L, Ebus ME, van Gerven MR, Zwijnenburg DA, Molenaar P, Hoyng LL, Dolman MEM, Essing AHW, Koopmans B, Helleday T, Drost J, van Boxtel R, Versteeg R, Koster J, Molenaar JJ#. (2021). Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma. Proc Natl Acad Sci U S A. 118(36):e2007898118

–

Helleday T#. (2021). Polθ inhibitors unchained. Nature Cancer. 2(6):581-583

–

Zhao Z, Gad H, Benitez-Buelga C, Sanjiv K, Xiangwei H, Kang H, Feng M, Zhao Z, Berglund UW, Xia Q#, Helleday T#. (2021). NEIL3 Prevents Senescence in Hepatocellular Carcinoma by Repairing Oxidative Lesions at Telomeres during Mitosis. Cancer Res. 81(15):4079-4093

–

Bivik Eding C, Köhler I, Verma D, Sjögren F, Bamberg C, Karsten S, Pham T, Scobie M, Helleday T, Berglund UW, Enerbäck C#. (2021). MTH1 inhibitors for the treatment of psoriasis. J Invest Dermatol. 141(8):2037-2048.e4

–

Hanna BMF, Michel M, Helleday T, Mortusewicz O#. (2021). NEIL1 and NEIL2 Are Recruited as Potential Backup for OGG1 upon OGG1 Depletion or Inhibition by TH5487. Int J Mol Sci. 22(9):4542

–

Rehling D, Zhang SM, Jemth AS, Koolmeister T, Throup A, Wallner O, Scaletti E, Moriyama T, Nishii R, Davies J, Desroses M, Rudd SG, Scobie M, Homan E, Berglund UW, Yang JJ, Helleday T#, Stenmark P#. (2021). Crystal structures of NUDT15 variants enabled by a potent inhibitor reveal the structural basis for thiopurine sensitivity. J Biol Chem. 296:100568

–

Oksvold MP, Berglund UW, Gad H, Bai B, Stokke T, Rein ID, Pham T, Sanjiv K, Øy GF, Norum JH, Smeland EB, Myklebust JH, Helleday T, Våtsveen TK#. (2021). Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma. Sci Rep. 11(1):6317

–

Baquero JM, Benítez-Buelga C, Rajagopal V, Zhenjun Z, Torres-Ruiz R, Müller S, Hanna BMF, Loseva O, Wallner O, Michel M, Rodríguez-Perales S, Gad H, Visnes T, Helleday T, Benítez J, Osorio A#. (2021). Small molecule inhibitor of OGG1 blocks oxidative DNA damage repair at telomeres and potentiates methotrexate anticancer effects. Sci Rep. 11(1):3490

2020

Pettke A, Tampere M, Pronk R, Wallner O, Falk A, Warpman Berglund U, Helleday T, Mirazimi A, Puumalainen MR#. (2020). Broadly Active Antiviral Compounds Disturb Zika Virus Progeny Release Rescuing Virus-Induced Toxicity in Brain Organoids. Viruses. 13(1):37

–

Tampere M, Pettke A, Salata C, Wallner O, Koolmeister T, Cazares-Körner A, Visnes T, Hesselman MC, Kunold E, Wiita E, Kalderén C, Lightowler M, Jemth AS, Lehtiö J, Rosenquist Å, Warpman-Berglund U, Helleday T, Mirazimi A, Jafari R, Puumalainen MR#. (2020). Novel Broad-Spectrum Antiviral Inhibitors Targeting Host Factors Essential for Replication of Pathogenic RNA Viruses. Viruses. 12(12):1423

–

Visnes T, Benítez-Buelga C, Cázares-Körner A, Sanjiv K, Hanna BMF, Mortusewicz O, Rajagopal V, Albers JJ, Hagey DW, Bekkhus T, Eshtad S, Baquero JM, Masuyer G, Wallner O, Müller S, Pham T, Göktürk C, Rasti A, Suman S, Torres-Ruiz R, Sarno A, Wiita E, Homan EJ, Karsten S, Marimuthu K, Michel M, Koolmeister T, Scobie M, Loseva O, Almlöf I, Unterlass JE, Pettke A, Boström J, Pandey M, Gad H, Herr P, Jemth AS, El Andaloussi S, Kalderén C, Rodriguez-Perales S, Benítez J, Krokan HE, Altun M, Stenmark P, Berglund UW, Helleday T#. (2020). Targeting OGG1 arrests cancer cell proliferation by inducing replication stress. Nucleic Acids Res. 48(21):12234-12251

–

Hanna BMF, Helleday T, Mortusewicz O#. (2020). OGG1 Inhibitor TH5487 Alters OGG1 Chromatin Dynamics and Prevents Incisions. 10(11):1483

–

Zhang SM, Desroses M, Hagenkort A, Valerie NCK, Rehling D, Carter M, Wallner O, Koolmeister T, Throup A, Jemth AS, Almlöf I, Loseva O, Lundbäck T, Axelsson H, Regmi S, Sarno A, Krämer A, Pudelko L, Bräutigam L, Rasti A, Göttmann M, Wiita E, Kutzner J, Schaller T, Kalderén C, Cázares-Körner A, Page BDG, Krimpenfort R, Eshtad S, Altun M, Rudd SG, Knapp S, Scobie M, Homan EJ, Berglund UW, Stenmark P, Helleday T#. (2020). Development of a chemical probe against NUDT15. Nat Chem Biol. 16(10):1120-1128

–

Mäkelä R, Arjonen A, Suryo Rahmanto A, Härmä V, Lehtiö J, Kuopio T, Helleday T, Sangfelt O, Kononen J, Rantala JK#. (2020). Ex vivo assessment of targeted therapies in a rare metastatic epithelial-myoepithelial carcinoma. Neoplasia. 22(9):390-398

–

Montanuy H, Camps-Fajol C, Carreras-Puigvert J, Häggblad M, Lundgren B, Aza-Carmona M, Helleday T, Minguillón J, Surrallés J#. (2020). High content drug screening for Fanconi anemia therapeutics. Orphanet J Rare Dis. 15(1):170

–

Škerlová J, Unterlass J, Göttmann M, Marttila P, Homan E, Helleday T, Jemth AS, Stenmark P#. (2020). Crystal structures of human PAICS reveal substrate and product binding of an emerging cancer target. J Biol Chem. 295(33):11656-11668

–

Friedrich S, Barbulescu R, Helleday T, Sonnhammer ELL#. (2020). MetaCNV – a consensus approach to infer accurate copy numbers from low coverage data. BMC Med Genomics. 13(1):76

–

Michel M, Homan EJ, Wiita E, Pedersen K, Almlöf I, Gustavsson AL, Lundbäck T, Helleday T, Warpman-Berglund U#. (2020). In silico Druggability Assessment of the NUDIX Hydrolase Protein Family as a Workflow for Target Prioritization. Front Chem. 8:443

–

Rudd SG, Gad H, Sanjiv K, Amaral N, Hagenkort A, Groth P, Ström CE, Mortusewicz O, Berglund UW, Helleday T#. (2020). MTH1 Inhibitor TH588 Disturbs Mitotic Progression and Induces Mitosis-Dependent Accumulation of Genomic 8-oxodG. Cancer Res. 80(17):3530-3541

–

Moukengue B, Brown HK, Charrier C, Battaglia S, Baud’huin M, Quillard T, Phame TM, Paterasg IS, Gorgoulis HI, Helleday T, Heymann D, Warpman-Berglund U, Orya B, Lamoureux F#. (2020). TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model. 53:102704

–

Scaletti ER, Vallin KS, Bräutigam L, Sarno A, Warpman-Berglund U, Helleday T, Stenmark P, Jemth AS#. (2020). MutT homologue 1 (MTH1) removes N6-methyl-dATP from the dNTP pool. Journal of Biological Chemistry. 295(15):4761-4772

–

Montanuy H, Martínez-Barriocanal A, Casado JA, Rovirosa L, Ramírez MJ, Nieto R, Carrascoso-Rubio C, Riera P, Gonzales A, Lerma E, Lasa A, Carreras-Puiqvert J, Helleday T, Bueren JA, Arango D, Minguillion J, Surralles J#. (2020). Gefitinib and afatinib show potential efficacy for Fanconi anemia-related head and neck cancer. Clinical Cancer Research. 26(12):3044-3057

–

Herr P, Boström J, Rullman E, Rudd SG, Vesterlund M, Lehtiö J, Helleday T, Maddalo G, Altun M#. (2020). Cell cycle profiling reveals protein oscillation, phosphorylation, and localization dynamics. Molecular & Cellular Proteomics. 19(4), 608-623

–

Peuget S, Zhu J, Sanz G, Singh M, Gaetani M, Chen X, Shi Y, Saei AA, Visnes T, Lindström MS, Rihani A, Moyano-Galceran L, Carlson JW, Hjerpe E, Joneburg U, Lehti K, Hartman J, Helleday T, Zubarev R, Selivanova G#. (2020). Thermal Proteome Profiling Identifies Oxidative-Dependent Inhibition of the Transcription of Major Oncogenes as a New Therapeutic Mechanism for Select Anticancer Compounds. Cancer Research. 80 (7): 1538-155

–

Rudd SG#, Tsesmetzis N, Sanjiv K, Paulin CB, Sandhow L, Kutzner J, Hed Myrberg I, Bunton, SS, Axelsson H, Zhang SM, Rasti A, Makela P, Coggins SA, Tao S, Branca RM, Mermelekas G, Wiita E, Lee S, Walfridsson J, Schinazi RF, Kim B, Lehtio J, Rassidakis GZ, Pokrovskaja-Tamm K, Warpman-Berglund U, Heyman M, Grander D, Lehmann S, Lundback T, Qian H, Henter JI, Scaller T, Helleday T, Herold N#. (2020). Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy. EMBO Mol Med. 12(3):e10419

–

Scaletti E, Claesson M, Helleday T, Jemth AS#, Stenmark P#. (2020). The first structure of an active mammalian dCTPase and its complexes with substrate analogues and products. J Mol Biol. 432 (4) 1126-1142

–

Das I, Gad H, Bräutigam L, Pudelko L, Tuominen R, Höiom V, Almlöf I, Rajagopa lV, Hansson J, Helleday T, Egyházi Brage S, Warpman-Berglund U#. (2020). AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma. Cell Death Differ. 27(7):2081-2098

2019

Espinoza JA, Zisi A, Kanellis DC, Carreras-Puigvert J, Henriksson M, Hühn D, Watanabe K, Helleday T, Lindström MS, Bartek J#. (2019). The antimalarial drug amodiaquine stabilizes p53 through ribosome biogenesis stress, independently of its autophagy-inhibitory activity. Cell Death Differ. 27(2):773-789

–

Michel M#, Visnes T, Homan EJ, Seashore-Ludlow B, Hedenström M, Wiita E, Vallin K, Paulin CBJ, Zhang J, Wallner O, Scobie M, Schmidt A, Jenmalm-Jensen A, Warpman-Berglund U, Helleday T#. (2019). Computational and Experimental Druggability Assessment of Human DNA Glycosylases. ACS Omega. 4(7):11642-11656

–

Hua X, Sanjiv K, Gad H, Pham T, Gokturk C, Rasti A, Zhao Z, He K, Feng M, Zang Y, Zhang J, Xia Q, Helleday T, Warpman–Berglund U#. (2019). Karonudib is a promising anticancer therapy in hepatocellular carcinoma. Ther Adv Med Oncol. 1:1758835919866960

–

Scaletti E, Jemth AS, Helleday T, Stenmark P#. (2019). Structural basis of inhibition of the human serine hydroxymethyltransferase SHMT2 by antifolate drugs. FEBS Lett. 593(14):1863-1873

–

Tepper S, Mortusewicz O, Członka E, Bello A, Schmidt A, Jeschke J, Fischbach A, Pfeil I, Petersen-Mahrt SK, Mangerich A, Helleday T, Leonhardt H, Jungnickel B#. (2019). Restriction of AID activity and somatic hypermutation by PARP-1. Nucleic Acids Res. 47(14):7418-7429

–

Jemth AS, Scaletti E, Carter M, Helleday T#, Stenmark P#. (2019). Crystal structure and substrate specificity of 8-oxo-dGTP hydrolase NUDT1 from Arabidopsis thaliana. Biochemistry. 58(7):887-899

–

Scaletti E, Jemth AS, Helleday T, Stenmark P#. (2019). Structural basis of inhibition of the human serine hydroxymethyltransferase SHMT2 by antifolate drugs. FEBS Lett. 593(14):1863-1873

–

Scaletti E, Jemth AS, Helleday T, Stenmark P#. (2019). Structural basis of inhibition of the human serine hydroxymethyltransferase SHMT2 by antifolate drugs. FEBS Lett. 593(14):1863-1873

–

Scaletti E, Jemth AS, Helleday T, Stenmark P#. (2019). Structural basis of inhibition of the human serine hydroxymethyltransferase SHMT2 by antifolate drugs. FEBS Lett. 593(14):1863-1873

–

2018

Lallo A, Gulati S, Schenk MW, Khandelwal G, Berglund UW, Pateras IS, Chester CPE, Pham TM, Kalderen C, Frese KK, Gorgoulis VG, Miller C, Blackhall F, Helleday T, Dive C#. (2018). Ex vivo culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics. Br J Pharmacol. 176(3):436-450

–

Visnes T, Cázares-Körner A, Hao W, Wallner O, Masuyer G, Loseva O, Mortusewicz O, Wiita E, Sarno A, Manoilov A, Astorga-Wells J, Jemth AS, Pan L, Sanjiv K, Karsten S, Gokturk C, Grube M, Homan EJ, Hanna BMF, Paulin CBJ, Pham T, Rasti A, Berglund UW, von Nicolai C, Benitez-Buelga C, Koolmeister T, Ivanic D, Iliev P, Scobie M, Krokan HE, Baranczewski P, Artursson P, Altun M, Jensen AJ, Kalderén C, Ba X, Zubarev RA, Stenmark P, Boldogh I, Helleday T#. (2018). Small-molecule inhibitor of OGG1 suppresses proinflammatory gene expression and inflammation. Science. 16;362(6416):834-839

–

Jemth AS, Gustafsson R, Bräutigam L, Henriksson L, Vallin KSA, Sarno A, Almlöf I, Homan E, Rasti A, Warpman-Berglund U, Stenmark P#, Helleday T#. (2018). MutT homologue 1 (MTH1) catalyzes the hydrolysis of mutagenic O6-methyl-dGTP. Nucleic Acids Res. 46(20):10888-10904

–

Burgos-Morón E, Calderón-Montaño JM, Pastor N, Höglund A, Ruiz-Castizo Á, Domínguez I, López-Lázaro M, Hajji N, Helleday T, Mateos S, Orta ML#. (2018). The Cockayne syndrome protein B is involved in the repair of 5-AZA-2′-deoxycytidine-induced DNA lesions. Oncotarget. 12;9(80):35069-35084

–

Gustafsson NMS#, Färnegårdh K, Bonagas N, Ninou AH, Groth P, Wiita E, Jönsson M, Hallberg K, Lehto J, Pennisi R, Martinsson J, Norström C, Hollers J, Schultz J, Andersson M, Markova N, Marttila P, Kim B, Norin M, Olin T, Helleday T#. (2018). Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination. Nat Commun. 9(1):3872

–

Mur P, Jemth AS, Bevc L, Amaral N, Navarro M, Valdés-Mas R, Pons T, Aiza G, Urioste M, Valencia A, Lázaro C, Moreno V, Puente XS, Stenmark P, Warpman-Berglund U, Capellá G, Helleday T, Valle L#. (2018). Germline variation in the oxidative DNA repair genes NUDT1 and OGG1 is not associated with hereditary colorectal cancer or polyposis. Hum Mutat. 39(9):1214-1225

–

Einarsdottir BO, Karlsson J, Söderberg EMV, Lindberg MF, Funck-Brentano E, Jespersen H, Brynjolfsson SF, Bagge RO, Carstam L, Scobie M, Koolmeister T, Wallner O, Stierner U, Berglund UW, Ny L, Nilsson LM, Larsson E, Helleday T, Nilsson JA#. (2018). A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma. Cell Death Dis. 9(8):810

–

Desroses M, Busker S, Astorga-Wells J, Attarha S, Kolosenko I, Zubarev RA, Helleday T, Grandér D, Page BDG#. (2018). STAT3 differential scanning fluorimetry and differential scanning light scattering assays: Addressing a missing link in the characterization of STAT3 inhibitor interactions. J Pharm Biomed Anal. 160:80-88

–

Berglund E, Maaskola J, Schultz N, Friedrich S, Marklund M, Bergenstråhle J, Tarish F, Tanoglidi A, Vickovic S, Larsson L, Salmén F, Ogris C, Wallenborg K, Lagergren J, Ståhl P, Sonnhammer E, Helleday T#, Lundeberg J#. (2018). Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity. Nat Commun. 9(1):2419

–

Riley AM, Unterlass J, Konieczny V, Taylor CW, Helleday T, Potter BVL#. (2018). A synthetic diphosphoinositol phosphate analogue of inositol trisphosphate. Medchemcomm. 9(7):1105-1113

–

Pudelko L, Edwards S, Balan M, Nyqvist D, Al-Saadi J, Dittmer J, Almlöf I, Helleday T, Bräutigam L#. (2018). An orthotopic glioblastoma animal model suitable for high-throughput screenings. Neuro Oncol. 20(11):1475-1484

–

Henriksson S, Groth P, Gustafsson N, Helleday T#. (2018). Distinct mechanistic responses to replication fork stalling induced by either nucleotide or protein deprivation. Cell cycle. 17(5):568-579

–

Carter M, Jemth AS, Carreras-Puigvert J, Herr P, Martínez Carranza M, Vallin KSA, Throup A, Helleday T#, Stenmark P#. (2018). Human NUDT22 Is a UDP-Glucose/Galactose Hydrolase Exhibiting a Unique Structural Fold. Structure. 26(2):295-303.e6

–

Page BDG#, Valerie NCK, Wright RHG, Wallner O, Isaksson R, Carter M, Rudd SG, Loseva O, Jemth AS, Almlöf I, Font-Mateu J, Llona-Minguez S, Baranczewski P, Jeppsson F, Homan E, Almqvist H, Axelsson H, Regmi S, Gustavsson AL, Lundbäck T, Scobie M, Strömberg K, Stenmark P, Beato M, Helleday T#. (2018). Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells. Nat Commun. 9(1):250

–

Thålin C, Lundström S, Seignez C, Daleskog M, Lundström A, Henriksson P, Helleday T, Phillipson M, Wallén H, Demers M#. (2018). Citrullinated histone H3 as a novel prognostic blood marker in patients with advanced cancer. PLoS One. 13(1):e0191231

–

Riley AM, Unterlass J, Konieczny V, Taylor CW, Helleday T, Potter BVL#. (2018). A synthetic diphosphoinositol phosphate analogue of inositol trisphosphate. Medchemcomm. 9(7):1105-1113

–

2017

Narwal M, Jemth AS, Gustafsson R, Almlöf I, Warpman Berglund U, Helleday T#, Stenmark P#. (2017). Crystal Structures and Inhibitor Interactions of Mouse and Dog MTH1 Reveal Species-Specific Differences in Affinity. Biochemistry. 57(5):593-603

–

Glimelius B, Melin B, Enblad G, Alafuzoff I, Beskow A, Ahlström H, Bill-Axelson A, Birgisson H, Björ O, Edqvist PH, Hansson T, Helleday T, Hellman P, Henriksson K, Hesselager G, Hultdin M, Häggman M, Höglund M, Jonsson H, Larsson C, Lindman H, Ljuslinder I, Mindus S, Nygren P, Pontén F, Riklund K, Rosenquist R, Sandin F, Schwenk JM, Stenling R, Stålberg K, Stålberg P, Sundström C, Thellenberg Karlsson C, Westermark B, Bergh A, Claesson-Welsh L, Palmqvist R, Sjöblom T#. (2017). U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden. Acta Oncol. 57(2):187-194

–

Rudling A, Gustafsson R, Almlöf I, Homan EJ, Scobie M, Warpman Berglund U, Helleday T, Stenmark P, Carlsson J#. (2017). Fragmented-based discovery and optimization of enzyme inhibitors by docking of commercial chemical space. J Med Chem. 60(19): 8160-8169

–

Llona-Minguez S#, Ghassemian A, Baranczewski P, Desroses M, Koolmeister T, Artursson P, Scobie M, Helleday T#. (2017). Structure-metabolism-relationships in the microsomal clearance of piperazin-1-ylpyridazines. Medchemcomm. 8(7):1553-1560

–

Llona-Minguez S#, Throup A, Steiner E, Lightowler M, Van der Haegen S, Homan E, Eriksson L, Stenmark P, Jenmalm-Jensen A, Helleday T. (2017). Novel spirocyclic systems via multicomponent aza-Diels-Alder reaction. Org Biomol Chem. 15(37):7758-7764

–

Carreras-Puigvert J#, Zitnik M, Jemth AS, Carter M, Unterlass JE, Hallström B, Loseva O, Karem Z, Calderón-Montaño JM, Lindskog C, Edqvist PH, Matuszewski DJ, Ait Blal H, Berntsson RPA, Häggblad M, Martens U, Studham M, Lundgren B, Wählby C, Sonnhammer ELL, Lundberg E, Stenmark P, Zupan B, Helleday T#. (2017). A comprehensive structural, biochemical and biological profiling of the human NUDIX hydrolase family. Nat Commun. 8(1):1541

–

Asim M#, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, Baridi A, Warren AY, Zhao W, Ogris C, McDuffus LA, Mascalchi P, Shaw G, Dev H, Wadhwa K, Wijnhoven P, Forment JV, Lyons SR, Lynch AG, O’Neill C, Zecchini VR, Rennie PS, Baniahmad A, Tavaré S, Mills IG, Galanty Y, Crosetto N, Schultz N, Neal D, Helleday T#. (2017). Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 8(1):374

–

Pudelko L, Rouhi P, Sanjiv K, Gad H, Kalderén C, Höglund A, Squatrito M, Schuhmacher AJ, Edwards S, Hägerstrand D, Berglund UW, Helleday T#, Bräutigam L#. (2017). Glioblastoma and glioblastoma stem cells are dependent on functional MTH1. Oncotarget. 8(49):84671-84684

–

Llona-Minguez S#, Fayezi S, Alihemmati A, Juárez-Jiménez J, Piedrafita FJ, Helleday T. (2017). Tetrahydrobenzothiophene carboxamides: Beyond the kinase domain and into the fatty acid realm. Bioorg Med Chem Lett. 27(18):4462-4466

–

Orta ML#, Pastor N, Burgos-Morón E, Domínguez I, Calderón-Montaño JM, Huertas Castaño C, López-Lázaro M, Helleday T, Mateos S#. (2017). Zebularine induces replication-dependent double-strand breaks which are preferentially repaired by homologous recombination. DNA repair. 57:116-124

–

Llona-Minguez S#, Häggblad M, Martens, Throup A, Loseva O, Jemth AS, Lundgren B, Scobie M, Helleday T#. (2017). Diverse heterocyclic scaffolds as dCTP pyrophosphatase 1 inhibitors. Part 1: Triazoles, triazolopyrimidines, triazinoindoles, quinoline hydrazones and arylpiperazines. Bioorg Med Chem Lett. 27(16):3897-3904

–

Llona-Minguez S#, Häggblad M, Martens U, Johansson L, Sigmundsson K, Lundbäck T, Loseva O, Jemth AS, Lundgren B, Jensen AJ, Scobie M, Helleday T#. (2017). Diverse heterocyclic scaffolds as dCTP pyrophosphatase 1 inhibitors. Part 2: Pyridone- and pyrimidinone-derived systems. Bioorg Med Chem Lett. 27(15):3219-3225

–

Tsuber V#, Kadamov, Brautigam, Berglund UW, Helleday T#. (2017). Mutations in Cancer Cause Gain of Cysteine, Histidine, and Tryptophan at the Expense of a Net Loss of Arginine on the Proteome Level. Biomolecules. 3;7(3)

–

Kolosenko I#, Yu Y, Busker S, Dyczynski M, Liu J, Haraldsson M, Palm Apergi C, Helleday T, Tamm KP, Page BDG, Grander D#. (2017). Identification of novel small molecules that inhibit STAT3-dependent transcription and function. PLoS One. 12(6):e017884

–

Jaiswal H, Benada J, Müllers E, Akopyan K, Burdova K, Koolmeister T, Helleday T, Medema RH, Macurek L#, Lindqvist A#. (2017). ATM/Wip1 activities at chromatin control Plk1 re-activation to determine G2 checkpoint duration. EMBO J. 36(14):2161-2176

–

Llona-Minguez S#, Höglund A, Ghassemian A, Desroses M, Calderón-Montaño JM, Burgos Morón E, Valerie NCK, Wiita E, Almlöf I, Koolmeister T, Mateus A, Cazares-Körner C, Sanjiv K, Homan E, Loseva O, Baranczewski P, Darabi M, Mehdizadeh A, Fayezi S, Jemth AS, Warpman Berglund U, Sigmundsson K, Lundbäck T, Jenmalm Jensen A, Artursson P, Scobie M, Helleday T. (2017). Piperazin-1-ylpyridazine Derivatives Are a Novel Class of Human dCTP Pyrophosphatase 1 Inhibitors. J Med Chem. 25;60(10):4279-4292

–

Vladimer GI, Snijder B, Krall N1, Bigenzahn JW, Huber KVM, Lardeau CH Sanjiv K, Ringler A Berglund UW, Sabler M, de la Fuente OL, Knöbl P, Kubicek S, Helleday T, Jäger U, Superti-Furga G#. (2017). Global survey of the immunomodulatory potential of common drugs. Nat Chem Biol. 13(6):681-690

–

Hagenkort A, Paulin CBJ, Desroses M, Sarno A, Wiita E, Mortusewicz O, Koolmeister T, Loseva O, Jemth AS, Almlöf I, Homan E, Lundbäck T, Gustavsson AL, Scobie M, Helleday T#. (2017). dUTPase inhibition augments replication defects of 5-Fluorouracil. Oncotarget 8(14):23713-2372

–

Herold N#, Rudd SG, Sanjiv K, Kutzner J, Bladh J, Paulin CBJ, Helleday T, Henter JI, Schaller T. (2017). SAMHD1 protects cancer cells from various nucleoside-based antimetabolites. Cell Cycle. 16(11):1029-1038

–

Thålin C, Daleskog M, Göransson SP, Schatzberg D, Lasselin J, Laska AC, Kallner A, Helleday T, Wallén H, Demers M#. (2017). Validation of an enzyme-linked immunosorbent assay for the quantification of citrullinated histone H3 as a marker for neutrophil extracellular traps in human plasma. Immunol Res. 65(3):706-712

–

Llona-Minguez S#, Höglund A, Wiita E, Almlöf I, Mateus A, Calderón-Montaño JM, Cazares-Körner C, Homan EJ, Loseva O, Baranczewski P, Jemth AS, Häggblad M, Martens U, Lundgren B, Artursson P, Lundbäck T, Jenmalm-Jensen A, Warpman Berglund U, Scobie M, Helleday T#. (2017). Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP pyrophosphatase 1. J Med Chem. 60(5):2148-2154

–

Herold N#, Rudd SG, Ljungblad L, Sanjiv K, Myrberg IH, Paulin CB, Heshmati Y, Hagenkort A, Kutzner J, Page BD, Calderón-Montaño JM, Loseva O, Jemth AS, Bulli L, Axelsson H, Tesi B, Valerie NC, Höglund A, Bladh J, Wiita E, Sundin M, Uhlin M, Rassidakis G, Heyman M, Tamm KP, Warpman-Berglund U, Walfridsson J, Lehmann S, Grandér D, Lundbäck T, Kogner P, Henter JI, Helleday T, Schaller T# (2017). Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies. Nat Med. 23(2):256-263

–

Gustafsson R, Jemth AS, Gustafsson Sheppard N, Färnegårdh K, Loseva O, Wiita E, Bonagas N, Dahllund L, Llona-Minguez S, Häggblad M, Henriksson M, Andersson Y, Homan E, Helleday T#, Stenmark P#. (2017). Crystal structure of the emerging cancer target MTHFD2 in complex with a substrate-based inhibitor. Cancer Res. 77(4):937-948

–

Ogris C#, Guala D, Helleday T, Sonnhammer EL#. (2017). A novel method for crosstalk analysis of biological networks: improving accuracy of pathway annotation. Nucleic Acids Res. 25;45(2):e8

2016

–

Ogris C#, Guala D, Helleday T, Sonnhammer EL#. (2017). A novel method for crosstalk analysis of biological networks: improving accuracy of pathway annotation. Nucleic Acids Res. 25;45(2):e8

2015

Herr P, Lundin C, Evers B, Ebner D, Bauerschmidt C, Kingham G, Palmai-Pallag T, Mortusewicz O, Frings O, Sonnhammer E, Helleday T#. (2015). A genome-wide IR-induced RAD51 foci RNAi screen identifies CDC73 involved in chromatin remodeling for DNA repair. Cell Discovery 1:15034

–

Coskun E, Jaruga P, Jemth AS, Loseva O, Scanlan LD, Tona A, Lowenthal MS, Helleday T, Dizdaroglu M#. (2015). Addiction to MTH1 protein results in intense expression in human breast cancer tissue as measured by liquid chromatography-isotope-dilution tandem mass spectrometry. DNA Repair (Amst). 33:101-10

–

Carter M, Jemth AS, Hagenkort A, Page BD, Gustafsson R, Griese JJ, Gad H, Valerie NC, Desroses M, Boström J, Warpman Berglund U, Helleday T#, Stenmark P#. (2015). Crystal structure, biochemical and cellular activities demonstrate separate functions of MTH1 and MTH2. Nature Commun. 6:7871

–

Zhao H, Sifakis EG, Sumida N, Millán-Ariño L, Scholz BA, Svensson JP, Chen X, Ronnegren AL, Mallet de Lima CD, Varnoosfaderani FS, Shi C, Loseva O, Yammine S, Israelsson M, Rathje LS, Németi B, Fredlund E, Helleday T, Imreh MP, Göndör A#. (2015). PARP1- and CTCF-Mediated Interactions between Active and Repressed Chromatin at the Lamina Promote Oscillating Transcription. Mol Cell. 59(6):984-97

–

Xie S, Mortusewicz O, Ma HT, Herr P, Poon RR, Helleday T#, Qian C#. (2015). Timeless Interacts with PARP-1 to Promote Homologous Recombination Repair. Mol Cell. 60(1):163-76

–

Xing M, Wang X, Palmai-Pallag T, Shen H, Helleday T, Hickson ID, Ying S#. (2015). Acute MUS81 depletion leads to replication fork slowing and a constitutive DNA damage response. Oncotarget. 6(35):37638-46

–

Tarish FL, Schultz N, Tanoglidi A, Hamberg H, Letocha H, Karaszi K, Hamdy FC, Granfors T, Helleday T#. (2015). Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair. Sci Transl Med. 7(312):312re11

–

Palazzo L, Thomas B, Jemth AS, Colby T, Leidecker O, Feijs K, Zaja R, Loseva O, Puigvert JC, Matic I, Helleday T, Ahel I#. (2015). Processing of Protein ADP-ribosylation by Nudix Hydrolases. Biochem J. 468(2):293-301

–

Llona-Minguez S#, Desroses M, Ghassemian A, Jacques SA, Eriksson L, Isacksson R, Koolmeister T, Stenmark P, Scobie M, Helleday T. (2015). Vinylic MIDA Boronates: New Building Blocks for the Synthesis of Aza-Heterocycles. Chemistry. 21(20):7394-8

–

Saleh A#, Gökturk C, Warpman-Berglund U, Helleday T, Granelli I. (2015). Development and validation of method for TH588 and TH287, potent MTH1 inhibitors and new anti-cancer agents, for pharmacokinetic studies in mice plasma. J Pharm Biomed Anal. 104:1-11

2014

–

Xie S, Mortusewicz O, Ma HT, Herr P, Poon RR, Helleday T#, Qian C#. (2015). Timeless Interacts with PARP-1 to Promote Homologous Recombination Repair. Mol Cell. 60(1):163-76

–

2013

Gubanova E, Issaeva N, Gokturk C, Djureinovic T, Helleday T#. (2013). SMG-1 suppresses CDK2 and tumor growth by regulating both the p53 and Cdc25A signaling pathways. Cell Cycle. 12(24):3770-80

–

Zalmas LP, Coutts AS, Helleday T, La Thangue NB#. (2013). E2F-7 couples DNA damage-dependent transcription with the DNA repair process. Cell Cycle. Aug 20;12(18)

–

Köpper F, Bierwirth C, Schön M, Kunze M, Elvers I, Kranz D, Saini P, Menon MB, Walter D, Sørensen CS, Gaestel M, Helleday T, Schön MP, Dobbelstein M#. (2013). Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity. Proc Natl Acad Sci U S A. 110(42):16856-61

–

Orta ML#, Calderón-Montaño JM, Domínguez I, Pastor N, Burgos-Morón E, López-Lázaro M, Cortés F, Mateos S#, Helleday T#. (2013). 5-Aza-2′-deoxycytidine causes replication lesions that require Fanconi anemia-dependent homologous recombination for repair. Nucleic Acids Res. 41(11):5827-36

–

Somaiah N#, Yarnold J, Lagerqvist A, Rothkamm K, Helleday T#. (2013). Homologous recombination mediates cellular resistance and fraction size sensitivity to radiation therapy. Radiother Oncol. 108(1):155-61

–

Burrell RA, McClelland SE, Endesfelder D, Groth P, Weller MC, Shaikh N, Domingo E, Kanu N, Dewhurst SM, Gronroos E, Chew SK, Rowan AJ, Schenk A, Sheffer M, Howell M, Kschischo M, Behrens A, Helleday T, Bartek J, Tomlinson IP, Swanton C#. (2013). Replication stress links structural and numerical cancer chromosomal instability. Nature. 494(7438):492-6

–

Al-Ubaidi FL, Schultz N, Loseva O, Egevad L, Granfors T, Helleday T#. (2013). Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer. Clin Cancer Res. 19(6);1-10

–

Kotova N, Vare D, Schultz N, Gradecka Meesters D, Stepnik M, Grawé J, Helleday T, Jenssen D#. (2013). Genotoxicity of alcohol is linked to DNA replication-associated damage and homologous recombination repair. Carcinogenesis. 34(2):325-30

–

He H, Tian D, Guo J, Liu M, Chen Z, Hamdy FC, Helleday T, Su M, Ying S#. (2013). DNA damage response in peritumoral regions of oesophageal cancer microenvironment. Carcinogenesis. 34(1):139-45

–

Jones RM, Mortusewicz O, Afzal I, Lorvellec M, García P, Helleday T#, Petermann E#. (2013). Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress. Oncogene. 32(32):3744-53

2012

Neumayer G, Helfricht A, Shim SY, Le HT, Lundin C, Belzil C, Chansard M, Yu Y, Lees-Miller SP, Gruss OJ, van Attikum H, Helleday T, Nguyen MD#. (2012). Targeting protein for xenopus kinesin-like protein 2 (TPX2) regulates γ-histone 2AX (γ-H2AX) levels upon ionizing radiation. J Biol Chem. 287(50):42206-22

–

Nicolay NH, Carter R, Hatch SB, Schultz N, Prevo R, McKenna WG, Helleday T, Sharma RA#. (2012). Homologous recombination mediates S-phase-dependent radioresistance in cells deficient in DNA polymerase eta. Carcinogenesis. 33(11):2026-34

–

Somaiah N, Yarnold JR#, Daley F, Pearson A, Gothard L, Rothkamm K#, Helleday T#. (2012). The relationship between homologous recombination repair and sensitivity of human epidermis to the size of daily doses over a 5-week course of breast radiotherapy. Clin Cancer Res. 18(19):5479-88

–

Elvers I, Hagenkort A, Johansson F, Djureinovic T, Lagerqvist A, Schultz N, Stoimenov I, Erixon K, Helleday T#. (2012). CHK1 activity is required for continuous replication fork elongation but not stabilization of post-replicative gaps after UV irradiation. Nucleic Acids Res. 40(17):8440-8

–

Ying S, Hamdy FC, Helleday T#. (2012). Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1. Cancer Res. 72(11):2814-21

–

Groth P, Orta ML, Elvers I, Majumder MM, Lagerqvist A, Helleday T#. (2012). Homologous recombination repairs secondary replication induced DNA double-strand breaks after ionizing radiation, Nucl. Acids Res. 40(14):6585-94

–

Fraser M, Zhao H, Luoto KR, Lundin C, Coackley CL, Chan N, Joshua AM, Bismar TA, Evans A, Helleday T, Bristow RG#. (2012). PTEN Deletion in Prostate Cancer Cells Does Not Associate With loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy. Clin Cancer Res. 18(4):1015-1027

–

Al–Ubaidi FL, Schultz N, Egevad L, Granfors T, Helleday T#. (2012). Castration therapy of prostate cancer results in downregulation of HIF-1α levels. Int J Radiat Oncol Biol Phys. 82(3):1243-8

–

Gubanova E, Brown BT, Ivanov SV, Helleday T, Mills GB, Yarbrough WG, Issaeva N#. (2012). Downregulation of SMG-1 in HPV-positive head and neck squamous cell carcinoma due to promoter hypermethylation correlates with improved survival. Clin Cancer Res. 18(5):1257-1267

–

Urbin SS, Elvers I, Hinz JM, Helleday T, Thompson LH#. (2012). Uncoupling of RAD51 focus formation and cell survival after replication fork stalling in RAD51D null CHO cells. Environ Mol Mutagen. 53(2):114-24

–

Abdallah QM, Phillips RM, Johansson F, Helleday T, Cosentino L, Abdel-Rahman H, Etzad J, Wheelhouse RT, Kiakos K, Bingham JP, Hartley JA, Patterson LH, Pors K#. (2012). Minor structural modifications to alchemix influence mechanism of action and pharmacological activity. Biochem Pharmacol. 83(11):1514-22

–

Chatzakos V, Slätis K, Djureinovic T, Helleday T, Hunt MC#. (2012). N-Acyl Taurines are Anti-Proliferative in Prostate Cancer Cells. Lipids. 47(4):355-61

–

Wilsker D, Chung JH, Pradilla I, Petermann E, Helleday T, Bunz F#. (2012). Targeted Mutations in the ATR Pathway Define Agent-Specific Requirements for Cancer Cell Growth and Survival. Mol Cancer Ther. 11(1):98-107

2011

Ström CE, Mortusewicz O, Finch D, Parsons JL, Lagerqvist A, Johansson F, Schultz N, Erixon K, Dianov GL, Helleday T#. (2011). CK2 phosphorylation of XRCC1 facilitates dissociation from DNA and single-strand break formation during base excision repair. DNA Repair. 10:961-9

–

Svensson LM, Jemth AS, Desroses M, Loseva O, Helleday T, Högbom M, Stenmark P. (2011). Crystal structure of human MTH1 and the 8-oxo-dGMP product complex. FEBS Lett. 585:2617-21

–

Segal-Raz H, Mass G, Baranes-Bachar K, Lerenthal Y, Wang SY, Chung YM, Ziv-Lehrman S, Ström CE, Helleday T, Hu MC, Chen DJ, Shiloh Y#. (2011). ATM-mediated phosphorylation of polynucleotide kinase/phosphatase is required for effective DNA double-strand break repair. EMBO Rep. 12(7):713-9

–

Elvers I, Johansson F, Groth P, Erixon K, Helleday T#. (2011). UV stalled replication forks by re-priming in human fibroblasts. Nucleic Acids Res. 39(16):7049-57

–

Al-Assar O, Mantoni T, Lunardi S, Kungham G, Helleday T, Brunner TB. (2011). Breast cancer stem-like cells show dominant homologous recombination due to a larger S- G2 fraction. Cancer Biol Ther. 11(12):1028-35

–

Stoimenov I, Schultz N, Gottipati P, Helleday T#. (2011). Transcription Inhibition by DRB Potentiates Recombinational Repair of UV Lesions in Mammalian Cells. PLoS One. 6(5):e19492

–

Kondo N, Takahashi A, Mori E, Noda T, Zdzienicka MZ, Thompson LH, Helleday T, Suzuki M, Kinashi Y, Masunaga S, Ono K, Hasegawa M, Ohnishi T#. (2011). FANCD1/BRCA2 Plays Predominant Role in the Repair of DNA Damage Induced by ACNU or TMZ. PLoS One. 6(5):e19659

–

Moskwa P, Buffa FM, Pan Y, Panchakshari R, Vischioni B, Parker A, Pezzella F, Gottipati P, Abdelmohsen K, Camps C, Ragoussis J, Kulshrestha R, Weinstock DM, Sharma RA, Gorospe M, Harris AL, Helleday T# and Chowdhury D#. (2011). miR-182-mediated down-regulation of BRCA1 impacts on the DNA damage response and breast cancer therapy. Molecular Cell, 41:210-20

–

Ström C, Johansson F, Erixon K and Helleday T. (2011). Poly (ADP-ribose) polymerase (PARP) inhibitors disrupt coordinated base excision repair incision and ligation in mammalian cells. Nucleic Acids Res. 39:3166-75

–

Noda T, Takahashi A, Kondo N, Mori E, Okamoto N, Nakagawa Y, Ohnishi K, Zdzienicka MZ, Thompson LH, Helleday T, Asada H, Ohnishi T#. (2011). Repair pathways independent of the Fanconi anemia nuclear core complex play a predominant role in mitigating formaldehyde-induced DNA damage. Biochem Biophys Res Commun. 404:206-10

–

Stoimenov I, Gottipati P, Schultz N and Helleday T#. (2011). Transcription inhibition causes DNA damage and triggers homologous recombination repair in mammalian cells. Mutation Research. 706:1-6

–

Bauerschmidt C#, Woodcock M, Stevens DL, Hill MA, Rothkamm K#, and Helleday T#. (2011). Cohesin phosphorylation and mobility of SMC1 at ionizing radiation induced DNA double strand breaks in human cells. Experimental Cell Research. 317:330-7

2010

Hawtin RE, Stockett DE, Wong OK, Lundin C, Helleday T, Fox JA#. (2010). Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks. Oncotarget. 1:606-19

–

Duro E, Lundin C, Ask, K, Sanchez-Pulido L, MacArtney TJ, Toth R, Ponting CP, Groth A, Helleday T, Rouse J#. (2010). Identification of the MMS22L-TONSL complex that promotes homologous recombination. Molecular Cell. 40:632-44

–

Chan N, Pires IM, Bencokova Z, Coackley C, Luoto KR, Bhogal N, Lakshman M, Gottipati P, Oliver FJ, Helleday T, Hammond EM#, Bristow RG#. (2010). Contextual synthetic lethality of cancer cell kill based on the tumour microenvironment. Cancer Research. 70:8045-54

–

Savolainen L, Cassel T and Helleday T#. (2010). The XPD subunit of TFIIH is required for transcription-associated but not DNA double-strand break-induced recombination in mammalian cells. Mutagenesis. 25:623-9

–

Petermann E#, Woodcock M, Helleday T#. (2010). Chk1 promotes replication fork progression by controlling replication initiation. Proc Natl Acad Sci USA. 107:16090-5

–

Higgins GS, Harris AL, Prevo R, Helleday T, McKenna WG, Buffa FM#. (2010). Overexpression of POLQ Confers a Poor Prognosis in Early Breast Cancer Patients. Oncotarget. 1:175-184

–

Blundred R, Myers K, Helleday T, Goldman A and Bryant HE#. (2010). Human RECQL5 overcomes thymidine induced replication stress. DNA Repair. 9:964-75

–

Groth P, Ausländer S, Majumder MM, Schultz N, Johansson F, Petermann E, Helleday T. (2010). Methylated DNA causes a physical block to replication forks independently of damage signalling, O⁶-methyl guanine or DNA single-strand breaks and results in DNA damage. Journal of Molecular Biology. 402:70-82

–

Issaeva N, Thomas HD, Pedley N, Djurenovic T, Kyle S, Zur R, Sleeth K, Stoimenov I, Chatzakos V, Mulligan E, Lundin C, Gubanova E, Harris AL, Sharma RA, Zdzienicka MZ, Curtin NJ and Helleday T#. (2010). 6-thioguanine selectively kills BRCA2 defective tumours and overcomes PARP inhibitor and cisplatin resistance. Cancer Research. 70(15):6268-76

–

MacKay C., Déclais A-C, Lundin C, Agostinho A, Deans AJ, MacArtney TJ, Hofmann K, Gartner A, West SC, Helleday T, Lilley DM, Rouse J#. (2010). Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by monoubiquitinated FANCD2. Cell. 142, 65-76

–

Gottipati P, Vischioni B, Schultz N, Solomons J, Bryant HE, Djureinovic T, Issaeva N, Sleeth K, Sharma RA and Helleday T#. (2010). Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Research. 70, 5389-98

–

Parsons JL, Dianova II, Finch D, Tait PS, Ström CE, Helleday T and Dianov GL#. (2010). XRCC1 phosphorylation by CK2 is required for its stability and efficient DNA repair. DNA repair. 9, 835-41

–

Beck H, Nähse V, Larsen MSY, Groth P, Clancy T, Lees M, Jørgensen M, Helleday T, Syljuåsen RG, Sørensen CS#. (2010). Regulators of Cyclin-Dependent Kinases are crucial for maintaining genome integrity in S-phase. Journal of Cell Biology. 37, 492-502

–

Petermann E, Orta L, Issaeva N, Schultz N and Helleday T#. (2010). Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51- mediated pathways for restart and repair. Molecular Cell. 37, 492-502

–

Loseva O, Jemth AS, Bryant HE, Schuler H, Lehtio L, Karlberg T, Helleday T#. (2010). Poly(ADP-ribose) polymerase-3 (PARP-3) is a mono-ADP ribosylase that activates PARP-1 in absence of DNA. Journal of Biological Chemistry. 285, 8054-60

–

Higgins GS, Prevo R, Lee Y-F, Helleday T, Muschel RJ, Taylor S, Yoshimura M, Hickson ID, Bernhard EJ, McKenna WG#. (2010). A siRNA Screen of Genes Involved in DNA Repair Identifies Tumour Specific Radiosensitisation by POLQ Knockdown. Cancer Research. 70, 2984-93

2009

McLachlan J, Fernandez S, Helleday T, Bryant HE#. (2009). Specific targeted gene repair using single stranded DNA oligonucleotides at an endogenous locus in mammalian cells uses homologous recombination. DNA Repair. 8, 1424‐33

–

Al‐Minawi AA, Lee Y‐F, Johansson F, Håkansson D, Lundin C, Saleh‐Gohari N, Schultz N, Jenssen D, Hinz JM and Helleday T#. (2009). The ERCC1/XPF endonuclease is required for completion of homologous recombination at interstrand crosslink‐stalled replication forks. Nucleic Acids Res. 37, 6400‐13

–

Bryant HE, Petermann E, Schultz N, Jemth A-S, Issaeva N, Johansson F, Fernandez S, McGlynn P, Helleday T#. (2009). PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination EMBO J, 28, 2601-15

–

Ying S, Myers K, Bottomley S, Helleday T, Bryant HE. (2009). BRCA2‐dependent homologous recombination is required for repair of Arsenite‐induced replication lesions in mammalian cells. Nucleic Acids Res. 37, 5105‐13

–

Lehtiö L, Jemth A-S, Collins R, Loseva O, Johansson A, Markova N, Hammarström M, Flores A, Holmberg-Schiavone L, Weigelt J, Helleday T#, Schüler H#, Karlberg T. (2009). Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. Journal of Medical Chemistry. 52, 3108-11

–

Savolainen L, Helleday T#. (2009). Transcription-associated recombination is independent of XRCC2 and mechanistically separate from homology-directed DNA double-strand break repair. Nucleic Acids Research. 37, 405-12

2008

Wilsker D, Petermann E, Helleday T, Bunz F#. (2008). Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control. Proc Natl Acad Sci U S A. 105, 20752-7

–

Cheng WH, Muftic D, Muftuoglu M, Dawut L, Morris C, Helleday T, Shiloh Y, Bohr VA#. (2008). WRN Is Required for ATM Activation and the S-Phase Checkpoint in Response to Interstrand Crosslink-induced DNA Double Strand Breaks. Molecular Biology of the Cell. 19, 3923-33

–

Rodriguez R, Hansen LT, Phear G, Scorah J, Spang-Thomsen M, Cox A, Helleday T, Meuth M#. (2008). Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11. Clinical Cancer Research. 14, 5476-83

–

Petermann E, Helleday T, Caldecott, KW#. (2008). Claspin promotes normal replication fork rates in human cells. Molecular Biology of the Cell. 19, 2373-8

–

Lehtiö L#, Collins R, van den Berg S, Johansson A, Dahlgren L-G, Hammarström M, Helleday T, Holmberg-Schiavone L, Karlberg T, Weigelt J. (2008). Zinc Binding Catalytic Domain of Human Tankyrase 1 Journal of Molecular Biology. 379, 136-45

–

Frumerie C, Sylwan L, Helleday T, Yu A, Haggård-Ljungquist E#. (2008). Bacteriophage P2 integrase: another possible tool for site-specific recombination in eukaryotic cells. Journal of Applied Microbiology. 105, 290-9

–

Gottipati P, Cassel TN, Savolainen L, Helleday T#. (2008). Transcription-associated recombination is dependent on replication in mammalian cells. Molecular and Cellular Biology. 28(1):154-64

–

Al-Minawi AA, Saleh-Gohari N, Helleday T#. (2008). The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells. Nucleic Acids Research. 36(1):1-9

2007

Jørgensen S, Elvers I, Trelle MB, Menzel T, Eskildsen M, Jensen ON, Helleday T, Helin K#, Sørensen CS#. (2007). The histone methyltransferase SET8 is required for S-phase progression. Journal of Cell Biology. 179(7):1337-45

–

Sleeth KM, Sørensen CS, Issaeva N, Dziegielewski J, Bartek J, Helleday T#. ^(2007).RPA mediates recombination repair during replication stress and checkpoint signalling is required for RPA association with RAD52 and displacement on DNA, Journal of Molecular Biology. 373(1), 38-47

–

Saberi A, Hochegger H, Szuts D, Lan L, Yasui A, Sale JE, Taniguchi Y, Murakawa Y, Hua W, Yokomori K, Helleday T, Teraoka H, Arakawa H, Buerstedde JM, Takeda S#. (2006). RAD18 and poly[ADP ribose]polymerase independently suppress the access of non-homologous end joining to double strand breaks and facilitate homologous recombination mediated repair, Molecular and Cellular Biology. 27(7), 2562-71

–

Renglin-Lindh A, Schultz N, Saleh-Gohari N, Helleday T#. (2007). RAD51C (RAD51L2) is involved in maintaining centrosome number in mitosis. Cytogenet Genome Res. 116(1-2), 38-45

2006

Bartkova J, Rezaei N, Liontos M, Karakaidos P, Vassiliou LVF, Issaeva N, Kletsas D, Kolettas E, Niforou K, Zoumpourlis VC, Takaoka M, Nakagawa H, Tort F, Fugger K, Johansson F, Sehested F, Andersen CL, Dyrskjot L, Orntoft T, Lukas J, Kittas C, Helleday T, Halazonetis TD#, Bartek J#, Gorgoulis VG#. (2006). Oncogene-induced senescence is an integral part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature. 444(7119);633-7

–

Johansson F, Lagerqvist A, Filippi S, Palitti F, Erixon K, Helleday T, Jenssen D. (2006). Caffeine delays replication fork progression and enhances UV-induced homologous recombination in Chinese hamster cell lines. DNA Repair. 5(12);1449-58

–

Bryant HE, Helleday T#. (2006). Inhibition of poly(ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Research. 34(6);1685-1691

–

Renglin Lindh A, Rafii S, Schultz N, Cox A, Helleday T#. (2006). Mitotic defects in XRCC3 variants T241M and D213N and their relation to cancer susceptibility. Human Molecular Genetics. 15(7);1217-1224

–

Bryant HE, Ying S, Helleday T#. (2006). Homologous Recombination is involved in repair of Chromium-induced DNA damage in mammalian cells. Mutation Research. 599(1-2);116-123

2005

Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T#. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose)polymerase Nature. 434(7035):913-7

–

El-Khamisy SF, Saifi GM, Weinfeld M, Johansson F, Helleday T, Lupski JR, Caldecott KW#. (2005). Defective DNA Single-Strand Break Repair in Spinocerebellar Ataxia with Axonal Neuropathy-1. Nature. 434(7029):108-13

–

Sørensen CS, Hansen LT, Dziegielewski J, Syljuåsen RG, Lundin C, Bartek J#, Helleday T#. (2005). The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nature Cell Biology.7(2); 195-201

–

Syljuåsen RG, Sørensen CS, Hansen LT, Fugger K, Lundin C, Johansson F, Helleday T, Sehested M, Lukas J, Bartek J#. (2005). Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Molecular and Cellular Biology. 25(9);3553-3562

–

Saleh-Gohari N, Bryant HE, Schultz N, Parker KM, Cassel TN, Helleday T#. (2005). Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Molecular and Cellular Biology. 25(16); 7158–7169

–

Lundin C, Erixon K, North M, Walters K, Jenssen D, Goldman AS#, Helleday T#. (2005). Methyl methanesulfonate (MMS) produces heat-labile DNA damage but no detectable in vivo DNA double-strand breaks. Nucleic Acids Research. 33(12);3799-811

–

Bavoux C, Leopoldino AM, Bergoglio V, O-Wang J, Ogi T, Bieth A, Judde JG, Pena SD, Poupon MF, Helleday T, Tagawa M, Machado C, Hoffmann JS, Cazaux C#. (2005). Up-regulation of the error-prone DNA polymerase κ promotes pleiotropic genetic alterations and tumorigenesis. Cancer Research. 65(1);325-330

2004

Saleh-Gohari N, Helleday T#. (2004). Strand invasion involving short tract gene conversion is specifically suppressed in BRCA2-deficient hamster cells. Oncogene. 23(56);9136-41

–

Bolderson E, Scorah J, Helleday T, Smtyhe C, Meuth M#. (2004). ATM is required for the cellular response to thymidine induced replication fork stress. Human Molecular Genetics. 13(23);2937-2945

–

Johansson F, Allkvist A, Erixon K, Malmvärn A, Nilsson R, Bergman A, Helleday T, Jenssen D#. (2004). Screening for genotoxicity using the DRAG assay: Investigation of halogenated environmental contaminants. Mutation Research. 563(1);35-47

–

Saleh-Gohari N, Helleday T#. (2004). Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells Nucleic Acids Research. 32(12);3683-3688

–

Kumari A, Schultz N, Helleday T#. (2004). p53 protects from DNA double-strand breaks at stalled replication forks in mammalian cells. Oncogene. 23(13);2320-2325

–

Mohindra A, Bolderson E, Stone J, Wells M, Helleday T, Meuth M#. (2004). A Tumour Derived Mutant Allele of XRCC2 Preferentially Suppresses Homologous Recombination at DNA Replication Forks. Human Molecular Genetics. 13(2);203-212

2003

Schultz N, Lopez E, Saleh-Gohari N, Helleday T#. (2003). Poly(ADP-ribose) Polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Research. 31(17);4959-4964

–

Hansen LT#, Lundin C, Helleday, T, Poulsen, HS, Sørensen CS, Petersen LN, Spang-Thomsen M. (2003). DNA repair rate and etoposide (VP16) resistance of tumor cell subpopulations derived from a single human small cell lung cancer. Lung Cancer 40(2):157-64

–

Hansen LT#, Lundin C, Spang-Thomsen M, Petersen LN, Helleday T. (2003). A role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. International Journal of Cancer. 105(4);472-479

–

Lundin C, Schultz N, Arnaudeau C, Mohindra A, Hansen-Tengbjerg L, Helleday T#. (2003). RAD51 is involved in repair of damage associated with DNA replication in mammalian cells. Journal of Molecular Biology. 328(3);521-535

–

Hinz JM, Helleday T#, Meuth M. (2003). Reduced apoptotic response to camptothecin in a CHO cell line deficient in the homologous recombination repair protein XRCC3, Carcinogenesis. 24(2);249-253

1998-2002

Mohindra A, Hays LE, Phillips EN, Preston BD, Helleday T, Meuth M#. (2002). Defects in homologous recombination repair in mismatch repair deficient tumour cell lines. Human Molecular Genetics. 11(18);2189-2200

–

Lundic C, Samuelsson MKR, Helleday T#. (2002). Overexpression of cyclin E does not affect homologous recombination in Chinese hamster cells. Biochemical and Biophysical Research Communications. 296(2);363-367

–

Lundin C, Erixon K, Arnaudeau C, Schultz N, Jenssen D, Meuth M, Helleday T#. (2002). Different roles for non-homologous end joining and homologous recombination following replication arrest in mammalian cells. Molecular and Cellular Biology. 22(16);5869-5878

–

Olsson G#, Belyaev I, Helleday T, Harms-Ringdahl M (2001) Effects of ELF electromagnetic field on intragenic recombination in SPD8/V79 Chinese hamster cells. Mutation Research. 493(1-2);55-66

–

Arnaudeau C, Lundin C, Helleday T#. (2001).Replication Fork-Associated Double-Strand Breaks are Predominantly Repaired by Homologous Recombination via an Exchange Mechanism in Mammalian Cells. Journal of Molecular Biology. 307(5);1235-1245

–

Helleday T, Johansson F, Jenssen D. (2001). The DRAG test: an assay for detection of genotoxic damage. Altern Lab Anim. 29(3):233-41

–

Arnaudeau C, Rozier L, Cazeaux C, Defais M, Jenssen D, Helleday T#. (2001). RAD51 supports spontaneous non-homologous recombination in mammalian cells, but not the corresponding process induced by topoisomerase inhibitors. Nucleic Acids Research. 29(3); 662-667

–

Arnaudeau C#, Tenorio Miranda E, Jenssen D, Helleday T. (2000). Inhibition of DNA synthesis is a potent mechanism by which cytostatic drugs induce homologous recomb-ination in mammalian cells. Mutation Research DNA repair. 461(3);221-228

–

Helleday T#, Nilsson R, Jenssen D. (2000). Arsenic[III] and heavy metal salts induce intrachromosomal homologous recombination in the hprt gene in V79 Chinese hamster cells. Environmental Molecular Mutagenesis. 35(2), 114-122

–

Arnaudeau C#, Helleday T, Jenssen D. (1999). The RAD51 protein supports homologous recombination by an exchange mechanism in mammalian cells. Journal of Molecular Biology. 289(5);1231-1238

–

Helleday T#, Tuominen KL, Berman Å, Jenssen D. (1999). Brominated flame retardants induce intragenic recombination in mammalian cells. Mutation Research. 439(2);137-147

–

Helleday T#, Arnaudeau C, Jenssen D. (1998). A partial hprt gene duplication generated by non-homologous recombination in V79 Chinese hamster cells is eliminated by homologous recombination. Journal of Molecular Biology. 279(4);687-694

–

Helleday T#, Arnaudeau C, Jenssen D. (1998). Effect of carcinogenic agents upon different mechanisms for intragenic recombination in mammalian cells. Carcinogenesis. 19(6);973-978

Contact

Want to know more about our research?

Click here